Immune checkpoint inhibitors (ICIs) have become the standard of care in the treatment of patients with advanced melanoma.1 All patients with clinical stage III and stage IV high-risk resectable melanoma (HRRM) are candidates for adjuvant systemic therapy with ICIs or with BRAF/MEK inhibitors (v-raf murine sarcoma viral oncogene homolog B and mitogen-activated protein kinase inhibitors) if the tumor of a given patient carries the BRAF V600E or V600K sequence variations. Here, BRAF is linked to melanoma.